Pirbuterol
Clinical data | |
---|---|
Trade names | Maxair |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a601096 |
Pregnancy category |
|
Routes of administration |
Inhalational (MDI) |
ATC code | R03AC08 (WHO) R03CC07 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | 38029-10-6 |
PubChem (CID) | 4845 |
IUPHAR/BPS | 7272 |
DrugBank | DB01291 |
ChemSpider | 4679 |
UNII | OG645J8RVW |
KEGG | D08387 |
ChEMBL | CHEMBL1094966 |
Chemical and physical data | |
Formula | C12H20N2O3 |
Molar mass | 240.30 g/mol 300.3 g/mol (acetate) |
3D model (Jmol) | Interactive image |
Chirality | Racemic mixture |
|
|
|
|
(what is this?) (verify) |
Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler (Maxair Autohaler).
Contents
Clinical use[edit]
Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid.[1][2]
Mode of action[edit]
Pharmacokinetics[edit]
After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[1]
Adverse effects[edit]
References[edit]
- ^ a b "Maxair Autohaler (pirbuterol acetate inhalation aerosol) For Oral Inhalation Only. U.S. Full Prescribing Information". 3M Pharmaceuticals. Northridge, CA 91324. Retrieved 7 March 2016.
- ^ Bianchi, Marina; Clavenna, Antonio; Bonati, Maurizio (2010). "Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000–2009 period". European Journal of Clinical Pharmacology. 66 (9): 929–936. doi:10.1007/s00228-010-0845-y. ISSN 0031-6970.
External links[edit]
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |